ID   AsPC1-R
AC   CVCL_XX79
DR   cancercelllines; CVCL_XX79
DR   GEO; GSM1906988
DR   GEO; GSM1906989
DR   GEO; GSM1906990
DR   Wikidata; Q93326176
RX   PubMed=27910856;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Gene deletion; HGNC; HGNC:6844; MAP2K4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Arg100Thr (c.299G>C); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys135Alafs*35 (c.403delT); ClinVar=VCV001069265; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Transcriptomics; Microarray.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C9120; Pancreatic ductal adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0152 ! AsPC-1
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 19-12-19; Last updated: 10-04-25; Version: 10
//
RX   PubMed=27910856; DOI=10.1038/cgt.2016.71; PMCID=PMC5159445;
RA   Mezencev R., Matyunina L.V., Wagner G.T., McDonald J.F.;
RT   "Acquired resistance of pancreatic cancer cells to cisplatin is
RT   multifactorial with cell context-dependent involvement of resistance
RT   genes.";
RL   Cancer Gene Ther. 23:446-453(2016).
//